| Vaxart is a clinical-stage biotechnology company primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology proprietary oral vaccine platform. Co.'s oral vaccines are designed to generate immune responses that protect against a range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Co.'s investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. In addition, Co. is in early development of its first therapeutic vaccine targeting cervical cancer and dysplasia caused by human papillomavirus. We show 18 historical shares outstanding datapoints in our VXRT shares outstanding history coverage, used to compute VXRT market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VXRT market cap history over the course of time is important for investors
interested in comparing VXRT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VXRT versus a peer is one thing; comparing
VXRT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VXRT can fluctuate over the course of history.
With this page we aim to empower investors researching VXRT by allowing them to research the VXRT market cap history.